SV
Therapeutic Areas
A2A Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AO-252 | Ovarian Cancer, Endometrial Cancer, Triple-Negative Breast Cancer (TNBC) | Phase 1 |
| MLL-Menin Inhibitor (via Biomea Fusion) | Leukemias (genetically defined) & certain solid cancers | Phase 1 |
| TYK2 Pseudokinase Inhibitor | Autoimmune Disorders | Preclinical |
| YAP-TEAD Inhibitor/Degrader | Cancers with YAP overexpression | Preclinical |
| KRAS Degrader | Cancers with KRAS mutations | Preclinical |
| AO-001 | Leukemia | Research |
Leadership Team at A2A Pharma
SS
Sotirios Stergiopoulos
President & CEO, Founder
EP
Edward Painter
Chairman & CIO, Founder
CL
Chaemin Lim
Chief Scientific Officer
RF
Robbin Frnka
Vice President of Clinical Operations
SC
Srikumar Chellappan
Advisory Board Member, Professor and Chair of Tumor Biology at Moffitt Cancer Center